Ipsen’s Kayfanda® Gets EU Approval for Rare Liver Disease

Ipsen (FR:IPN) has released an update.

Ipsen’s drug Kayfanda® (odevixibat) has received EU approval to treat cholestatic pruritus in patients over six months old with Alagille Syndrome, a rare liver disease. The approval is based on Phase III trial results which demonstrated significant improvement in itch severity and sleep quality, with a safety profile similar to placebo. This marks a significant advancement in Ipsen’s portfolio for rare cholestatic liver diseases, also noted for their recent EU approval of Iqirvo® (elafibranor) for Primary Biliary Cholangitis.

For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.